This month's Research Video Series dives into the HD Buzz article, "Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam". According to the article, PTC Therapeutics shared new data from the long-term extension of PIVOT-HD, the Phase 2 clinical trial of votoplam, the daily pill designed to lower huntingtin (HTT) protein in people with Huntington’s disease (HD).

HDYO Research Video Series is sponsored by: uniQure, Ferrer, Prilenia, Neurocrine Biosciences, Teva Pharmaceutical, Skyhawk Therapeutics, Novartis, Wave Life Sciences, Roche, Alnylam and the Griffin Foundation.